SEC Comment Letter for Edesa Biotech, Inc. (EDSA) (CIK 0001540159) (EDSA) — Feb 27, 2020
Edesa Biotech, Inc. (EDSA) (CIK 0001540159)
Date: Feb. 27, 2020 · CIK: 0001540159 · Accession: 0000000000-20-001802
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236608
Letter
February 27, 2020 Kathi Niffenegger Chief Financial Officer Edesa Biotech, Inc. 100 Spy Court Markham, ON L3R 5H6 Canada Re:Edesa Biotech, Inc. Registration Statement on Form S-1 Filed February 25, 2020 File No. 333-236608 Dear Ms. Niffenegger: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jonathan Friedman, Esq.
Show Raw Text
February 27, 2020
Kathi Niffenegger
Chief Financial Officer
Edesa Biotech, Inc.
100 Spy Court
Markham, ON L3R 5H6 Canada
Re:Edesa Biotech, Inc.
Registration Statement on Form S-1
Filed February 25, 2020
File No. 333-236608
Dear Ms. Niffenegger:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jonathan Friedman, Esq.